The stock is likely to react negatively to the clinical trial failure and R&D shutdown. However, the significant cost savings, strong cash balance, and ongoing strategic review (potentially leading to a sale) could limit downside or create a speculative opportunity. Traders should monitor for updates on the strategic review and the company's ability to generate the projected $60-70 million in annualized cash flow from YUPELRI.
Price Chart
Executive Summary
Theravance Biopharma's Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint, prompting the company to wind down the program. In response, the company is restructuring, cutting costs by ~60% ($70M), reducing its workforce by ~50%, and accelerating a strategic review that could include a sale. Despite the setback, the company maintains a strong cash position (~$400M expected) and a profitable commercial product, YUPELRI.
Key Financial Metrics
Key Facts
- Phase 3 CYPRESS study for ampreloxetine failed to meet primary endpoint (OHSA Composite Score).
- Company is winding down the ampreloxetine program and its entire R&D function.
- Organizational restructuring will reduce operating expenses by ~60% (~$70 million) and impact ~50% of the workforce.
- Strategic Review Committee is accelerating its review of alternatives to maximize shareholder value, including a potential sale of the company.
- Company expects ~$400 million in cash by end of Q1 2026, driven by recent milestone payments.
- YUPELRI net sales grew 12% YoY in FY 2025 to $266.6 million, and the company expects a $100 million TRELEGY milestone in 2026.
Financial Impact
Cost savings of ~$70 million annually, one-time severance costs of $5-7 million, and a $326.5 million cash balance as of year-end 2025.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| YUPELRI | $266.6M | +12.0% |
Risk Factors
- The failure of the CYPRESS study eliminates a key future growth driver, leaving the company reliant on YUPELRI and potential milestones.
- The strategic review may not result in a transaction, leaving the company as a smaller, less diversified entity.
- The restructuring could lead to loss of key talent and operational disruption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-022572 |
| Document: tm267846d1_8k.htm | 0001104659-26-022572 |
| Document: 0001104659-26-022572-index-headers.html | 0001104659-26-022572 |
| Document: 0001104659-26-022572.txt | 0001104659-26-022572 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | DEFA14A | $17.03 $17.03 | · 0.00% | ▼ −0.23% | — |
Aug 21, 2026 6w ago | DEFM14A | $17.01 $17.05 | ▲ +0.24% | ▲ +0.76% | — |
Aug 11, 2026 7w ago | PREM14A | $16.91 $17.06 | ▲ +0.89% | ▲ +1.95% | — |
Aug 10, 2026 7w ago | 8-K | $16.91 $17.06 | ▲ +0.89% | ▲ +1.80% | — |
Jun 29, 2026 13w ago | 8-K | $17.06 $16.86 | ▼ −1.17% | ▼ −0.89% | — |
Jun 23, 2026 14w ago | 8-K | $17.27 $16.81 | ▼ −2.66% | ▼ −4.60% | — |
May 7, 2026 21w ago | 8-K | $17.02 $15.92 | ▼ −6.46% | ▼ −9.60% | — |
Mar 3, 2026 30w ago | 8-K | $13.96 $16.23 | ▼ −16.26% | ▼ −20.66% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access